We aimed to develop a microarray genotyping system for multiplex analysis of a panel of single nucleotide polymorphisms (SNPs) in genes encoding proteins involved in blood pressure regulation, and to apply this system in a pilot study demonstrating its feasibility in the pharmacogenetics of hypertension. A panel of 74 SNPs in 25 genes involved in blood pressure regulation was selected from the SNP databases, and genotyped in DNA samples of 97 hypertensive patients. The patients had been randomized to double-blind treatment with either the angiotensin II type 1 receptor blocker irbesartan or the â 1 -adrenergic receptor blocker atenolol. Genotyping was performed using a microarray based DNA polymerase assisted 'minisequencing' single nucleotide primer extension assay with fluorescence detection. The observed genotypes were related to the blood pressure reduction using stepwise multiple regression analysis. The allele frequencies of the selected SNPs were determined in the Swedish population. The established microarray-based genotyping system was validated and allowed unequivocal multiplex genotyping of the panel of 74 SNPs in every patient. Almost 7200 SNP genotypes were generated in the study. Profiles of four or five SNP-genotypes that may be useful as predictors of blood pressure reduction after antihypertensive treatment were identified. Our results highlight the potential of microarray-based technology for SNP genotyping in pharmacogenetics. Pharmacogenetics
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Introduction
The most abundant form of genetic variation are the single nucleotide polymorphisms (SNPs) that occur on the average at one out of every thousand bases in the human genome [1, 2] . As a result of the efforts of the SNP consortium, which comprises a collaboration between 14 major pharmaceutical companies, and the Human Genome Project [1] , there are over four million SNPs in public databases. Depending on where in the genome a SNP occurs, it may have different consequences on the phenotypic level. SNPs in the coding regions of genes may alter the function or the structure of the encoded proteins. While most of the SNPs are located in non-coding regions of the genome and have no direct known impact on the phenotype of an individual, they are useful as genetic markers because they may be inherited linked to the functional variants of physically closely located genes.
Hypertension is a quantitative trait caused by multiple factors that interact through pathways involving cardiac function, blood volume, salt regulation, peripheral vascular tone and endothelial function [3] . Many of the components of the blood pressure regulating pathways are proteins that vary in structure and activity among individuals owing to SNPs in the genes encoding them. Twin studies show that heritable components explain approximately one-half of the variance in blood pressure [4, 5] . Because genetic factors contribute to hypertension, there is good reason to hypothesize that genetic factors also contribute to individual responses to treatment with antihypertensive drugs. A large interindividual variation in the response to antihypertensive treatment is well documented [6, 7] . Despite attempts to use biochemical indicators, such as plasma renin activity, or metabolic characteristics as predictors of individual drug response, no such predictor has yet been identified to be of clinical importance [8, 9] .
We have recently found that the insertion/deletion polymorphism in the angiotensin-converting enzyme (ACE) gene predicted the reduction in blood pressure in hypertensive patients treated with an angiotensin II type 1 (AT 1 )-receptor blocker, but not in patients treated with a â 1 -adrenergic receptor (â 1 -AR) blocker [10] . A SNP in the aldosterone synthase gene (CYP11B2 À344 T/C) has also been found to be predictive of the systolic blood pressure reduction in hypertensive patients treated with irbesartan [11] . These studies suggest that pharmacogenetic analyses could be used as tools to achieve the optimal therapy. The unimodal frequency distribution of the response to treatment with antihypertensive drugs on the population level shows that many factors are involved [7] . In this study, we hypothesized that a combination of SNPs in genes known to be involved in blood pressure regulation would be powerful for predicting individual responses to antihypertensive drug treatment.
To facilitate simultaneous analysis of multiple SNPs in blood pressure-related genes, we developed a microarray-based genotyping system that utilizes 'minisequencing' single nucleotide primer extension [12] . This reaction principle has been adapted to a variety of assay formats [13] , and allows specific genotyping of most SNPs at the same reaction conditions, which is a particularly advantageous feature for multiplex genotyping in the microarray format. In our system, the primers are immobilized covalently on microscope slides in an 'array of arrays' format [14] that allows genotyping of a panel of SNPs in multiple samples on each slide. We applied the microarray-based minisequencing system to genotype a panel of 74 SNPs in blood pressure regulating candidate genes in DNA samples from hypertensive patients who had been treated with either of two antihypertensive drugs with different mechanisms of action.
Materials and methods
Study populations and blood samples DNA samples from 97 hypertensive patients from the double-blind parallel group 'Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol' (SILVHIA) trial [15] were analysed. The patients were randomized to treatment with either an AT 1 -receptor blocker (irbesartan) or a â 1 -AR blocker (atenolol). The results presented in this study are reported after 3 months of monotherapy. In 66% of the subjects receiving irbesartan and 39% of the subjects receiving atenolol, the dose was doubled after 6 weeks of treatment. However, neither for irbesartan nor for atenolol were the doses significantly related to the change in blood pressure (data not shown). The reduction in seated systolic blood pressure (SBP) and diastolic blood pressure (DBP) was recorded in a strictly standardized manner, as previously described in detail [10, 15] . The two treatment groups showed a similar reduction in SBP and DBP. Table 1 presents the basic characteristics of the patients.
The study was approved by the ethics committee of the Medical Faculty of Uppsala University (DNr 01-378).
A pooled sample consisting of equal amounts of DNA from 150 healthy Swedish blood donors was analysed to validate the SNPs and to determine the population frequencies of the SNP alleles. DNA was extracted from the blood samples using QiAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) or the Wizard Genomic DNA Purification Kit (Promega, Madison, Wisconsin, USA).
SNPs and primers
Ninety-eight SNPs in candidate genes were identified from the literature and the dbSNP (www.ncbi.nlm.nih. gov/SNP) and TSC (The SNP consortium, http:// snp.cshl.org/) databases. They are described in greater detail in Table 2 . The polymerase chain reaction (PCR) primers were designed using the Primer Analysis Software Oligo, version 6.15 (Molecular Biology Insights Inc, Cascade, Colorado, USA) to have similar T m values, two or three A-and/or C-residues at their 39-ends and universal primer sequences at their 59-ends. The primers were synthesized by Interactiva Biotechnologie GmbH (Ulm, Germany) or by Sigma-Genosys (Cambridge, UK). The sequences of the primers are available from the authors upon request.
PCR
PCR primers for 49 fragments comprising 74 SNPs were combined into eight multiplex PCR reactions containing two to 10 primer pairs, generating PCR products of different sizes. The fragments were amplified using a touchdown PCR-program [16] 100 ìl of PCR reaction buffer supplied with the enzyme. The multiplex PCR reactions had been optimized with respect to MgCl 2 , enzyme and primer concentrations. The success of the PCR was evaluated on 8% polyacrylamide gels.
Preparation of microarrays
The minisequencing primers were covalently immobilized on CodeLink TM Activated slides (previously 3D-Link slides, Motorola, Northbrook, Illinois, USA) by mediation of a 59-NH 2 group [17] . The NH 2 -modified primers were applied to the slides at a 25 ìmol/l concentration in 400 mmol/l sodium bicarbonate buffer, pH 9.0, by contact printing using a ProSys 5510A spotter (Cartesian Technologies Inc., Irvine, California, USA) equipped with four Stealth Micro Spotting Pins (SMP3; TeleChem International Inc., Sunnyvale, California, USA) resulting in spots with a diameter of 160 ìm. The oligonucleotides were printed in duplicate spots with a centre-to-centre distance of 200 ìm in an 'array of arrays' format with the same spacing as the wells of a 384-well microtitre plate [14] with four columns and 14 rows on each slide. A fluorescently labelled oligonucleotide was included as control for the immobilization process and for scanning of the arrays.
Microarray minisequencing reactions
The multiplex PCR products from each sample were combined, precipitated with ethanol and the DNA pellet was resuspended in 46 ìl of water. After denaturation of the DNA at 95 8C for 2 min, 14 ìl of a buffer containing 4.5 mmol/l NaCl, 50 mmol/l TrisHCl, pH 8.0, 5 mmol/l Na 2 -EDTA was added, and 15 ìl of the DNA solution was used in four parallel Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. reaction wells on the slides. A custom made silicon rubber grid placed on top of each microscope slide was used to form 56 separate reaction chambers [14] . A heated aluminium block holding three microscope slides was used for the reactions. After incubation for 40 min at 37 8C, the slides were briefly rinsed in a solution containing 5 mmol/l Tris-HCl pH 8.0, 0.5 mmol/l Na 2 -EDTA, 100 mmol/l NaCl, 0.1% Triton X-100 followed by rinsing with water. The minisequencing reaction mixtures contained one of the four TAMRA-labelled ddNTPs (ddATP NEL474, ddCTP NEL473, ddGTP NEL475 or ddUTP NEL472 PerkinElmer Life Sciences, Boston, Massachusetts, USA) and the other three ddNTPs unlabelled at a concentration of 0.5 ìmol, 0.75 U of DynaSeq DNA polymerase (gift from Finnzymes OY, Helsinki, Finland) or Thermo Sequenase DNA Polymerase (Amersham Biosciences, Uppsala, Sweden) in 26 mmol/l Tris-HCl pH 9.5, 6.5 mmol/l MgCl 2 , 0.1% Triton X-100. Fifteen ìl of reaction mixture was added to the reaction wells on the slides preheated to 55 8C, followed by incubation for 15 min. The slides were then briefly rinsed in water followed by washing for 2 min with 50 mmol/l NaOH, and twice for 5 min with 3 mmol/l sodium citrate, 30 mmol/l NaCl, 0.1% SDS, pH 7.0 at 65 8C and finally briefly rinsed with water. The slides were allowed to dry at room temperature before fluorescence scanning.
Fluorescence scanning and data interpretation
The fluorescence signals were detected using an array scanner (ScanArray 5000, Perkin-Elmer Life Sciences, Boston, Massachusetts, USA). The fluorescence intensity values were extracted with the QuantArray software supplied with the scanner. Using an algorithm, the mean values of the signals from the duplicate spots were corrected for the average background measured beneath each 'subarray'. The ratio between the fluorescence signal from one of the alleles and the sum of the fluorescence signals from both possible alleles at each SNP site was calculated to assign the genotypes.
Minisequencing in microtitre plates
Solid-phase minisequencing in microtitre plates with 3 H-labelled dNTPs was used to determine the allele frequencies of the SNPs in pooled DNA samples essentially as described previously [12, 18] , with the exception that a biotin residue for immobilization of the PCR products in the streptavidin-coated microtitre well was incorporated in a secondary PCR reaction with a biotinylated primer complementary to the universal sequence on the specific PCR primer. The ratio between the 3 H-dNTPs incorporated was normalized against the ratio in a heterozygous sample. If no heterozygous reference sample was available, the specific activities of the tritium labelled nucleotides ( 3 HdATP TRK633 69 Ci/mmol, 3 H-dCTP TRK625 46 Ci/ mmol, 3 H-dGTP TRK627 41 Ci/mmol, 3 H-dTTP TRK576 124 Ci/mmol, Amersham Biosciences) were used for normalization. Solid-phase minisequencing also served as reference method [12] .
Statistical analysis
For the SNPs with a frequency over 5% for the minor allele, Hardy-Weinberg equilibrium was assessed by comparison of the observed and expected genotype frequencies using the chi-square test with one degree of freedom. The Genepop web program (http://wbiomed.curtin.edu.au/genepop) [19] was used to calculate pairwise linkage disequilibrium (LD). Haplotypes were designated using the expectation maximization algorithm in the Haplo program (http://info.med.yale.edu/ genetics/kkidd) [20] . Subsets of SNPs required for distinguishing between haplotypes [21] were identified by visual inspection of the haplotypes.
The relationship between genotypes and change in blood pressure was first analysed using factorial oneway ANOVA (Statview 5, SAS Institute Inc., Cary, North Carolina, USA) to evaluate which of the genotypes of the 74 SNPs were related to the changes in SBP or DBP in the irbesartan and atenolol group separately. Four univariate analyses were performed for each of the individual SNPs. SNPs demonstrating a P , 0.10 were entered as independent variables in forward stepwise multiple regression models with one of the four possible combinations of SBP/DBP and irbesartan/atenolol as a dependent variable. In these models, P , 0.01 was set for retention of the independent variables in the models in order to reduce the effect of multiple testing by reducing the P-value accepted. Two-tailed significance levels were used. No formal correction for multiple testing was applied.
Results
The candidate genes were chosen based on their function in the renin-angiotensin-aldosterone, adrenergic and endothelial systems, and the lipid metabolism, respectively. A panel of 98 genetic variants in these genes was assembled for prediction of individual responses to treatment with antihypertensive drugs (Table 2 ). This panel comprised a small number of SNPs that had been shown or suggested to be involved in blood pressure regulation in the published literature.
Most of the SNPs in the panel were located in coding or regulatory regions of the candidate genes, but also a few SNPs in non-coding regions close to the genes (, 1.5 kb) were included. When possible, SNPs with published allele frequencies from 10% to 90% were selected. The allele frequencies in the Swedish population of the initially selected SNPs were determined by quantitative minisequencing analysis [12, 18] of a pooled sample containing DNA from 150 healthy individuals of Swedish origin. Based on this analysis, 24 SNPs were excluded from the panel for SNP profiling because they had a minor allele frequency of less than 1% in the Swedish population (16 SNPs) or due to PCR failure (8 SNPs). Over one-half of the SNPs, especially those with even allele distribution, had similar frequencies in Sweden as in the population where they had been identified (Table 3) . Seventy-four SNPs with allele frequencies ranging from 1% to 50% for their minor allele were included in the panel to genotype the DNA samples from hypertensive patients. Figure 1 presents a fluorescence scan image of a microarray where the SNPs included in the panel have been genotyped by minisequencing in samples from 12 of the patients. After fluorescence scanning of the arrays, the results are interpreted with the aid of an algorithm that extracts the signals from the microarray, and assigns the genotypes according to the ratio of the fluorescence signal from one of the alleles to the sum of the fluorescence signals from both alleles at each SNP site. As shown in Fig. 2 , the signal ratios for each SNP fall within one of three distinct, non-overlapping clusters that define the three possible genotypes unequivocally. Although the limits for the clusters of ratios vary depending on the sequence context of the SNPs, the ratios defining the genotype of the SNPs differ from each other on average by 0.32.
Using the microarray-based system, the panel of SNPs was genotyped in DNA samples from the 97 hypertensive patients participating in the study. As a consequence of the stringent criteria applied for defining the genotypes, approximately 20% of the genotypes were assigned after repeating the microarray-based analysis with a primer of the opposite polarity, or by verification of individual genotypes in the microtitre plate format of the minisequencing method. As a result of this strategy, a genotype was assigned for each SNP in every patient, and thus almost 7200 genotypes were generated. The genotypes of four SNPs (CYP11B2 T267C, AGTR1 A50058C, ADRB1 A145G, ADRB2 T1217C) were also determined individually by the reference method in all of the study samples. In addition, 200 randomly selected genotypes (8%) were redetermined by the reference method. Fully concordant genotyping results were obtained by the individual analysis and by the multiplex microarray-based genotyping, evidencing for the accuracy of the microarray system. The assigned genotypes conformed to HardyWeinberg expectations with the exception of the three SNPs in the AT 2 receptor gene, the C1165G SNP in the â 1 -adrenergic receptor gene and the G134A SNP in the renin gene (P , 0.001).
The allele frequencies for the panel of SNPs calculated from the individual patient samples are shown in Table  3 . With the exception of the SNPs REN G134A,
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. ADRB1 C1165G, ADRB2 G1342C and LPL G7360A, the allele frequencies identified in the hypertensive patients were identical to those in the pooled sample representing healthy blood donors.
The most probable haplotypes were determined using the expectation maximization algorithm based on the genotypes of the SNPs in eight of the candidate genes (Fig. 3 ). This analysis revealed that the allelic diversity of these genes is explained by three to six major haplotypes with a frequency of more than 5%. This analysis also shows that only two or three SNPs per gene define the haplotypes in 73% to 95% of the individuals analysed.
Of the 97 individuals with hypertension included in the study, one-half had been treated with atenolol and half with irbesartan. There was no difference in the basic characteristics between the two treatment groups, and both groups showed a similar reduction in SBP and DBP at three months of treatment (Table 1) . Because the reduction in blood pressure was unrelated to the doses of the two drugs, the doses were not evaluated as confounders in the statistical analysis. Those SNPs that were related to a change in blood pressure by univariate analysis were subjected to stepwise multiple regression analyses relating the genotypes of the SNPs to changes in blood pressure. This analysis revealed profiles of four or five SNPs that appeared as significant predictors of the reduction in SBP and DBP (Table 4) .
According to the calculation of pairwise linkage disequilibrium by the Genepop program, the two SNPs in the adrenergic receptor AE 2 in the group treated with atenolol, as well as the two SNPs in the ADRB2-gene that predicted both the SBP and DBP responses, are in LD, respectively. In the irbesartan-treated group, SNPs in the genes encoding angiotensinogen, ACE and aldosterone synthase were significant predictors of blood pressure reduction. The SNP G12257A in the ACE gene is in complete LD with the ACE I/D polymorphism, which was shown to predict the reduction in blood pressure in the same patients treated with irbesartan in our previous study [10] . In both treatment groups, the SNPs in the endothelin type B receptor (G40A) and the endothelial nitric oxide synthase (eNOS) (A498G) genes were predictors of SBP reduction. Of the SNPs in genes encoding components of lipid metabolism, the same SNP in the apolipoprotein A gene (A1449G) emerged as predictor of both SBP and DBP response to irbesartan. The SNP in the hepatic lipase gene (A110G) showed opposite effects on DBP response in the irbesartan and atenolol groups. In both treatment groups, the combined SNP genotype profiles explain as much as 44% to 56% of the reduction in SBP and DBP.
Discussion
In this study, we have established a robust microarraybased minisequencing system for genotyping a panel of 74 SNPs in 25 genes encoding proteins that potentially determine the pharmacodynamics of individual responses to antihypertensive treatment. The system proved to be robust and allowed accurate genotyping of all SNPs in every sample. Using this genotyping system, we were able to identify combinations of a few SNPs that predicted approximately 50% of the variation in the individual drug responses in two groups of hypertensive patients that had been subjected to monotherapy with one of two different antihypertensive drugs, a â 1 -AR blocker or an AT 1 -receptor blocker. The number of subjects in our study was low, and the results discussed below should be considered as hypothesis-generating and need to be confirmed in a larger sample set.
Certain features of the combinations of genetic variants that we identified as predictors of antihypertensive response are of particular interest. First, none of the investigated SNPs in the genes encoding the â 1 -AR or the AT 1 -receptor, which are the targets for irbesartan and atenolol, respectively, were useful predictors. The reasons for this could be that a relevant SNP was not included in the panel due to allelic heterogeneity of the genes, or that other steps in the physiological chains involved in the action of a drug are more important. The latter assumption might be supported by the fact that SNPs in the aldosterone synthase, ACE and angiotensinogen genes, which are all important components in the renin-angiotensin-aldosterone system, were among the genetic variants that were predictive for the response to the AT 1 -receptor blocker. Similarly, SNPs in the â 2 -adrenergic and adrenergic AE 2 receptors were predictors for the response to â-blockade. Second, both the endothelin type B receptor and the eNOS genes were found in the combinations that predicted the SBP response to both drugs, suggesting that an effect mediated by the endothelium is a common
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. action for both drugs. Third, although the SNPs APOA A1449G and EDNRB G40A predicted both the changes in SBP and DBP, most of the SNPs, found to be of interest predicted either SBP or DBP. This finding further emphasizes the fact that SBP and DBP are different entities, determined mainly by different mechanism, such as aortic stiffness and peripheral resistance. Finally, genes encoding components in lipid metabolism were found to be of predictive value for the blood pressure response to these antihypertensive drugs. This finding is in accordance with epidemiological studies showing a relationship between different lipid variables and blood pressure [22] [23] [24] , which was the rational for including these genes in the analysis. Potentially interesting for future pharmacogenetic use is the finding that one SNP (A110G), causing an amino acid substitution in the hepatic lipase gene, predicted positive response to treatment with atenolol but not to treatment with irbesartan. Five patients had the 'favourable' genotype combination predicting response in SBP upon treatment with irbesartan. They showed a mean reduction in SBP of 45 mmHg, while the reduction of SBP in the other patients in this treatment group was as low as 11 mmHg. The complete 'favourable' genotype combination was present in only one or two patients from the other treatment groups. AGTR1 A50058C  CETP A128C  REN A279C  ACE A10578G  ACE A14521G  ADRB1 A145G  AGT A1237G  AGTR1 A49954G  AGTR2 A4303G  APOA A1449G  CETP A1300G  CETP A311G  ENOS A498G  LIPC A110G  REN A1442G  ACE C14488A  CETP C146A  CETP C147A  ADRA2A C787G  ADRB1 C1165G  CASR C3031G  LPL C9040G  ACE C10514T  ADRB3 C3246T  AGT C1015T  AGTR1 C5245T  APOB C711T  APOE C4070T  LDLR C16730T  MLR C1825T  PPARG C1575T  ACE G12257A  ADRA2A G1817A  ADRB2 G1309A  AGT G1218A  AGTR2 G1675A  APOB G10108A  CETP G1335A  CETP G571A  EDNRA G125A  EDNRB G40A  ENOS G2996A  ENOS G9767A  LIPC G89A  LPL G7360A  PPARG G1043A  REN G134A  ACE G14480C  ADRB2 G1342C  LPL G7315C  ADRA2A G278T  AGTR2 G4297T  CASR G2956T  ENOS G20455T  ENOS G7002T  AGTR1 T4955A  ACE T10527C  ADRB2 T1217C  ADRB2 T1244C  ADRB3 T827C  AGT T1198C  APOE T3932C  CYP11B2 T267C  EDNRA T89C  LDLR T20001C  PPARA T39067C  AGTR1 T5052G  REN T1456G  REN T164G Ratio allele 1 / (allele 1 + allele 2) Haplotype frequencies for eight of the candidate genes for blood pressure regulation. Haplotypes with a frequency of . 5% are shown. The order of the SNPs in the haplotypes is the same as in Table 3 . SNPs marked with a circle symbolize the smallest number of SNPs needed to distinguish the haplotypes in this set of samples. Dashes indicate the same nucleotide as in the most common haplotype.
for allelic heterogeneity of the genes. However, it is notable that only five out of the 13 SNPs that constituted the profiles predicting SBP and DBP reduction, after antihypertensive treatment, encode an amino acid change in the corresponding protein, and could thus directly affect its biological function. The remaining predictor SNP variants are presumably in LD with functional variants not included in the analysis. According to our haplotype analysis of eight of the candidate genes containing multiple SNPs, three to six major haplotypes account for most of the allelic variation of these genes. The haplotypes describe the pattern of LD between adjacent SNPs and, if the haplotype structures had been known in advance, a smaller number of SNPs than those included in the genotyping panel would have been sufficient to capture the genetic variation of these eight genes.
Currently, large panels of SNPs located throughout the human genome are available in public databases. The assessment of the relationship between genetic variation and complex traits is hampered by the lack of high-throughput methods that would facilitate simultaneous genotyping of many SNPs in large sample sets; a review on SNP technology is provided elsewhere [25] . Homogeneous PCR assays with allele-specific probes or PCR primers, performed with real-time fluorescence detection [26, 27] or primer extension assays in combination with mass spectrometric detection [28] , have recently been the most favoured methods. Because these methods do not allow multiplex analysis of several SNPs per reaction, they are of limited use when large panels of SNPs are to be analysed in each sample. Microarray-based technology offers the potential of highly multiplexed assays, and DNA polymerase-assisted primer extension allows accurate SNP genotyping, even in low or intermediate density microarray formats. The standard microarray formats, originally designed for transcript profiling, are impractical for SNP typing in large sample sets because, typically, only one sample is analysed per microscope slide [29, 30] , which is the reason why these methods have not been widely applied beyond the 'proof of principle' level. The 'array of arrays' format employed in this study removed this obstacle, and allowed us to genotype multiple individual samples on each slide. The capacity of the genotyping system can be increased four-fold by using different fluorophores on each of the four nucleotides [31, 32] , instead of a single fluorophore, as was the case in this study. The major limitation in throughput of our method, as for all other SNP-genotyping methods, is imposed by the necessity of amplifying the regions spanning the SNPs by PCR. Provided that this problem can be solved, automation of the microarray-based assay would allow a genotyping throughput approaching that required for genotyping SNPs in all human genes, especially if a haplotype tagging strategy [21] were to be used for minimizing the number of SNPs required.
A limitation of our study is the small number of patients included. Another concern is the genotyping of multiple SNPs facilitated by the microarray-based genotyping system. Because this pilot study was mainly intended to establish and test the applicability of the genotyping system, and the results generated are exploratory, no formal adjustment for multiple testing was used. However, the stringent criteria of P , 0.01 was applied for inclusion of SNPs in the models in order to minimize the chance of type II errors. The issue of potentially false positive results due to multiple testing encountered in our study of 74 SNPs will be further accentuated in the future, when whole genome scans of thousands of SNP markers will become feasible owing to the development of high-throughput genotyping technology. It is obvious that traditional correction for multiple testing, such as Bonferoni correction, will not be applicable to this type of studies, because millions of study subjects would be required to achieve formal statistical significance. Hence, other solutions to the problem of multiple testing are needed. One solution would be to split the analysed sample population into two parts, and to use the second half of the samples to test the validity of the results obtained
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. in the first half of the samples. Unfortunately, this approach would have been possible in our pilot study only if a much larger number of samples had been available. Another, more fundamental solution would be to include samples from family members in the study, and to apply statistical genetics methods to interpret the genotyping data [33] .
In conclusion, the preliminary results obtained in this pilot study need to be reproduced in a larger, prospective study to validate the identified pharmacogenetic profiles. We believe that, in the future, when a panel of predictive pharmacogenetic markers has been identified, multiplex genotyping assays such as the one designed here will be valuable as routine diagnostic tools for designing the optimal individualized drug treatment for hypertensive patients.
